Sistla Krishna, MD
Geriatric Medicine · Houston, TXNPI 1811939382
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $771 and has fallen 77.7% since, to $172 in 2025.
Across 102 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$471
- Novo Nordisk$421
- Amarin Pharma, Inc.$337
- Boehringer Ingelheim$259
- Johnson & Johnson$125
- Sanofi-aventis U.S. LLC$77
- plus $384 from 10 others
What the payments were for
- Food & beverage$2,06199%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $471 |
| Novo Nordisk | 26 | $421 |
| Amarin Pharma, Inc. | 20 | $337 |
| Boehringer Ingelheim | 14 | $259 |
| Johnson & Johnson | 1 | $125 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Lilly USA, LLC | 4 | $73 |
| Dexcom, Inc. | 3 | $67 |
| Amgen(2 entities) | 4 | $67 |
| Pulmonx Corporation | 1 | $63 |
| Exact Sciences | 1 | $30 |
| Abbott | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| AbbVie | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,073 in reported general payments places this provider in the 85th percentile of 275 geriatric medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $66,711 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 23 | $36,492 |
| EliquisApixaban | 20 | $31,194 |
| MounjaroTirzepatide | 21 | $30,138 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $23,438 |
| TrulicityDulaglutide | 15 | $22,989 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $20,501 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $15,248 |
| FarxigaDapagliflozin Propanediol | 11 | $13,227 |
| VascepaIcosapent Ethyl | 22 | $10,437 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $7,892 |
| Icosapent Ethyl | 13 | $6,561 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $3,262 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 27 | $3,241 |
| Atorvastatin Calcium | 284 | $2,848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $421 | $66,71141 claims |
| Lilly USA, LLCMounjaro, Trulicity | $73 | $53,12736 claims |
| Boehringer IngelheimSynjardy Xr | $259 | $36,49223 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $77 | $23,43813 claims |
| AstraZenecaFarxiga | $471 | $13,22711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 275 geriatric medicine providers in Texas.
Other geriatric medicine in Houston
- George TaffetHouston$9K
- Adeeba AkhtarHouston$6K
- Anil ThakerHouston$4K
- Kathryn AgarwalHouston$4K
- Aimee GarciaHouston$3K
- Radhika HariharanHouston$3K
- Jerome WassersteinHouston$3K
- Teresa AlbrightHouston$2K
- Rechelle AsirotHouston$1K
- Elenita RosadoHouston$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.